HAVN Life Sciences Inc. (HAVLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HAVN Life Sciences Inc. (HAVLF) trades at $0.00 with AI Score 53/100 (Grade B). HAVN Life Sciences Inc. Market cap: $2,565, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for HAVLF: HAVLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HAVLF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HAVLF: 1/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →HAVN Life Sciences Inc. (HAVLF) Healthcare & Pipeline Overview
HAVN Life Sciences Inc. is a biotechnology firm specializing in the research and development of psychopharmacological products from plants and fungi, alongside natural health care solutions. The company focuses on standardized extraction methodologies for psychoactive compounds, positioning itself within the nascent but evolving psychedelic medicine and wellness markets.
What Is the Investment Thesis for HAVLF?
HAVN Life Sciences Inc. presents an investment thesis centered on its early-stage R&D in the nascent but potentially transformative psychedelic medicine and natural health product markets. The company's core value proposition lies in its focus on developing standardized and quality-controlled extraction methodologies for psychoactive compounds like psilocybin, psilocin, and baeocystin from Psilocybe spp. mushrooms. This scientific rigor is crucial for establishing credibility and ensuring product consistency, which could be a significant differentiator as the psychedelic therapy landscape evolves. Additionally, the development of natural health products from non-regulated compounds provides an immediate market pathway. While the company currently operates with a negative profit margin of -8117.8% and a market capitalization of 3K, indicative of its development stage, its beta of -0.31 suggests a low correlation with broader market movements. Key growth catalysts include potential advancements in regulatory frameworks for psychedelic research, successful development of proprietary extraction technologies, and the commercialization of its natural health product lines. Investors would be evaluating the long-term potential of its intellectual property and market positioning in a high-growth, albeit high-risk, biotechnology segment.
Based on FMP financials and quantitative analysis
HAVLF Key Highlights
- Market Capitalization of 3K reflects the company's early-stage development and small scale within the biotechnology sector.
- Profit Margin of -8117.8% indicates significant investment in research and development without substantial revenue generation, typical for a pre-commercial biotech firm.
- Gross Margin of 32.4% suggests some operational efficiency in its existing activities, likely related to its natural health product segment or early-stage product sales.
- Beta of -0.31 indicates a low correlation with the overall market, potentially offering some diversification benefits, though this can be volatile for micro-cap stocks.
- The company operates with a lean team of 6 employees, emphasizing its R&D focus and early-stage operational structure.
Who Are HAVLF's Competitors?
HAVLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HAVLF's Key Strengths?
- Specialized focus on psychopharmacological R&D from natural sources, addressing an emerging market.
- Emphasis on standardized and quality-controlled extraction, crucial for regulatory acceptance and product efficacy.
- Dual approach of developing both regulated psychoactive compounds and non-regulated natural health products.
- Lean operational structure with a small team, potentially allowing for agile R&D.
What Are HAVLF's Weaknesses?
- Negative profit margin of -8117.8% indicates significant unprofitability and high R&D costs relative to revenue.
- Small market capitalization of 3K and limited employee count (6) suggest early-stage development and potential resource constraints.
- Reliance on a highly regulated and evolving market (psychedelic medicine) with uncertain timelines for commercialization.
- Unknown disclosure status on the OTC market may deter some institutional investors.
What Could Drive HAVLF Stock Higher?
- Successful development and patenting of proprietary standardized extraction methodologies for psychoactive compounds, enhancing competitive advantage and potential licensing opportunities.
- Introduction of new natural health care products from non-regulated compounds to the market, potentially generating initial revenue streams and brand recognition.
- Positive advancements in regulatory frameworks in key jurisdictions regarding the research, medical use, or decriminalization of psychedelic compounds, opening new market pathways.
- Continued scientific research and preclinical studies demonstrating the efficacy and safety of their extracted compounds for specific therapeutic applications.
- Formation of strategic partnerships or collaborations with academic institutions or larger pharmaceutical companies to accelerate R&D or facilitate market access.
What Are the Key Risks for HAVLF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant regulatory hurdles and uncertainties surrounding the research, development, and commercialization of psychedelic compounds, which could delay or prevent market entry.
- High cash burn rate and negative profit margin (-8117.8%) typical of early-stage biotech, indicating a continuous need for capital to fund R&D and operations, risking dilution.
- Intense competition from other biotechnology firms, established pharmaceutical companies, and academic institutions also exploring psychedelic medicine and natural health products.
- The 'Unknown' disclosure status on the OTC market poses substantial transparency risks, making it difficult for investors to assess financial health and operational progress.
- Limited liquidity and extreme price volatility inherent with trading on the 'OTC Other' tier and a 3K market cap, making it challenging to buy or sell shares.
What Are the Growth Opportunities for HAVLF?
- Advancement in Psychedelic-Assisted Therapies: The global psychedelic drugs market is projected to grow significantly as clinical research demonstrates efficacy for conditions like depression, PTSD, and addiction. HAVN Life Sciences' focus on standardized extraction of psilocybin, psilocin, and baeocystin positions it to supply high-quality, consistent compounds for clinical trials and, eventually, commercial therapeutic use. As regulatory bodies like the FDA and Health Canada continue to explore pathways for these substances, HAVN's foundational work in quality control could become a critical asset, potentially leading to partnerships with larger pharmaceutical companies or direct market entry in the next 3-5 years as therapies gain approval.
- Development of Proprietary Extraction Methodologies: HAVN Life Sciences is actively developing methodologies for the standardized and quality-controlled extraction of psychoactive compounds. This focus on intellectual property in extraction science could yield significant competitive advantages. Proprietary methods ensure consistent purity and potency, which are essential for pharmaceutical-grade products. These patented or trade-secret processes could be licensed to other developers, sold as raw materials, or used to create their own branded products. The market for high-purity, standardized botanical extracts is growing, and HAVN's expertise could capture a share, particularly as the demand for research-grade psychedelics increases over the next 2-4 years.
- Expansion of Natural Health Product Portfolio: Beyond regulated psychoactive compounds, HAVN Life Sciences is also developing natural health care products from non-regulated compounds. This segment offers a more immediate revenue pathway and broader market access, as these products typically face fewer regulatory barriers. The global natural health products market is robust and growing, driven by increasing consumer interest in wellness and preventative health. By leveraging its expertise in botanical extraction and formulation, HAVN can introduce a range of science-backed, plant-based supplements and wellness products. This diversification could provide stable revenue streams and brand recognition within the next 1-3 years, supporting the longer-term R&D efforts.
- Strategic Partnerships and Collaborations: Given the capital-intensive nature of biotechnology R&D and the complex regulatory landscape of psychedelic medicine, forming strategic partnerships is a significant growth opportunity. Collaborations with academic institutions, larger pharmaceutical companies, or specialized contract research organizations could accelerate HAVN's research, provide access to advanced clinical trial capabilities, and facilitate market entry. Such partnerships could also de-risk development costs and provide validation for HAVN's extraction technologies and product formulations. These alliances could materialize as early as the next 1-2 years, significantly impacting the company's trajectory.
- Advancements in Regulatory Frameworks for Psychedelics: The evolving regulatory landscape surrounding psychedelic compounds presents a substantial growth opportunity. As more jurisdictions consider decriminalization, medical legalization, or even recreational use, the market for HAVN's core products could expand dramatically. Favorable regulatory shifts would reduce market entry barriers, accelerate clinical development, and increase investor confidence. HAVN's proactive engagement in developing standardized products positions it well to capitalize on these changes. While the exact timeline is uncertain, continued progress in regulatory reform over the next 5-10 years could unlock a multi-billion-dollar market for psychedelic-based therapies and research materials, directly benefiting companies like HAVN.
- Geographic Market Expansion: While currently headquartered in Canada, HAVN Life Sciences has the opportunity to expand its market reach beyond its domestic borders. As regulatory environments for psychedelic research and natural health products vary globally, identifying and entering new markets where conditions are favorable could significantly increase its customer base and revenue potential. This could involve establishing distribution networks for its natural health products or seeking regulatory approvals for its psychopharmacological compounds in countries with progressive healthcare policies. Such expansion could begin within the next 3-5 years, contingent on successful product development and market research.
What Opportunities Does HAVLF Have?
- Growing scientific interest and clinical evidence supporting the therapeutic potential of psychedelics for mental health.
- Expansion into the broader natural health and wellness market with non-regulated plant-based products.
- Potential for strategic partnerships with larger pharmaceutical companies or research institutions.
- Advancements in regulatory frameworks that could open up new markets for psychedelic-based therapies.
What Threats Does HAVLF Face?
- Stringent and unpredictable regulatory environment for psychoactive compounds, potentially delaying or preventing market entry.
- Intense competition from other biotechnology firms and pharmaceutical companies entering the psychedelic space.
- Significant capital requirements for R&D and clinical trials, posing funding challenges for a small company.
- Public perception and stigma associated with psychedelic substances, despite therapeutic potential.
What Are HAVLF's Competitive Advantages?
- Proprietary methodologies for standardized and quality-controlled extraction of psychoactive compounds, ensuring purity and consistency.
- Early-mover advantage and specialized R&D focus within the emerging and highly regulated psychedelic medicine sector.
- Scientific expertise in identifying and isolating specific genera directive compounds from plants and fungi.
- Potential for intellectual property protection around its extraction processes and product formulations.
What Does HAVLF Do?
HAVN Life Sciences Inc., incorporated in 2020 and headquartered in Richmond, Canada, is a biotechnology company dedicated to the pioneering field of psychopharmacological product development. The company's core mission revolves around leveraging the therapeutic potential of compounds derived from various plants and fungi. A significant area of its research and development efforts is directed towards establishing robust methodologies for the standardized and quality-controlled extraction of psychoactive compounds. This includes a particular focus on Psilocybe spp. mushrooms and their key genera directive compounds, such as psilocybin, psilocin, and baeocystin. The emphasis on standardization is critical for ensuring consistency, purity, and efficacy, which are paramount for future clinical applications and regulatory acceptance in the pharmaceutical and natural health sectors. Beyond controlled substances, HAVN Life Sciences Inc. also extends its expertise to the development of natural health care products utilizing non-regulated compounds. This dual approach allows the company to address both the emerging market for psychedelic-assisted therapies and the broader wellness market with innovative, plant-based solutions. With its foundational work in extraction science and product formulation, HAVN Life Sciences aims to contribute to the advancement of mental health treatments and natural wellness, operating with a lean team of 6 employees from its Port Moody, CA, and Richmond, Canada, locations.
What Products and Services Does HAVLF Offer?
- Conducts research and development of psychopharmacological products derived from various plants and fungi.
- Develops standardized and quality-controlled methodologies for extracting psychoactive compounds from sources like Psilocybe spp. mushrooms.
- Focuses on isolating and purifying specific genera directive compounds, including psilocybin, psilocin, and baeocystin.
- Formulates and develops natural health care products using non-regulated compounds.
- Aims to contribute to the advancement of mental health treatments through plant and fungi-based solutions.
- Engages in scientific exploration to ensure consistency, purity, and efficacy of its extracted compounds for potential therapeutic applications.
How Does HAVLF Make Money?
- Research and development of proprietary extraction methods for psychoactive compounds from plants and fungi.
- Development and potential commercialization of pharmaceutical-grade psychoactive compounds for clinical research and therapeutic applications.
- Formulation and sale of natural health care products derived from non-regulated compounds.
- Potential licensing of its standardized extraction technologies to other entities in the biotechnology and pharmaceutical sectors.
What Industry Does HAVLF Operate In?
HAVN Life Sciences Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically targeting the emerging psychopharmacological and natural health product segments. The broader biotechnology sector is characterized by intensive research and development, long product development cycles, and significant regulatory hurdles. HAVN Life Sciences distinguishes itself by focusing on compounds from plants and fungi, including psychoactive substances like psilocybin, which are gaining increasing attention for their therapeutic potential in mental health. This niche positions the company within the 'psychedelic medicine' market, a segment projected for substantial growth as clinical trials advance and regulatory bodies consider broader applications. The competitive landscape includes other biotech firms exploring psychedelic compounds, as well as established pharmaceutical companies and natural health product manufacturers. HAVN Life Sciences' emphasis on standardized extraction methodologies is crucial for establishing a competitive edge in a market where product consistency and purity are paramount for both regulatory approval and consumer trust.
Who Are HAVLF's Key Customers?
- Academic and clinical research institutions conducting studies on psychedelic compounds.
- Pharmaceutical companies seeking standardized, high-purity psychoactive compounds for drug development.
- Consumers interested in natural health care products for wellness and preventative health.
- Potential future patients receiving psychedelic-assisted therapies, pending regulatory approvals and commercialization.
How HAVN Life Sciences Inc. Is Valued
HAVN Life Sciences Inc. carries a market capitalization of 3K, placing it in the micro-cap category. Relative to its peer group, HAVLF's quantitative score of 53/100 is below the peer average of 76/100.
Company Profile
HAVN Life Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Port Moody, CA. The company is led by CEO Tim Moore. HAVLF has traded publicly since 2021.
F-Score 3/9Financial Health
HAVN Life Sciences Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HAVLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on psychopharmacological R&D from natural sources, addressing an emerging market.
- Emphasis on standardized and quality-controlled extraction, crucial for regulatory acceptance and product efficacy.
- Dual approach of developing both regulated psychoactive compounds and non-regulated natural health products.
- Lean operational structure with a small team, potentially allowing for agile R&D.
Bear Case
- Negative profit margin of -8117.8% indicates significant unprofitability and high R&D costs relative to revenue.
- Small market capitalization of 3K and limited employee count (6) suggest early-stage development and potential resource constraints.
- Reliance on a highly regulated and evolving market (psychedelic medicine) with uncertain timelines for commercialization.
- Unknown disclosure status on the OTC market may deter some institutional investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HAVLF Latest News
No recent news available for HAVLF.
HAVLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HAVLF.
Price Targets
Wall Street price target analysis for HAVLF.
HAVLF MoonshotScore
What does this score mean?
The MoonshotScore rates HAVLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tim Moore
CEO
Tim Moore serves as the Chief Executive Officer of HAVN Life Sciences Inc., overseeing the strategic direction and operational execution of the biotechnology company. His background is rooted in leading and managing enterprises, particularly within nascent and evolving industries. With a focus on innovation and market development, Mr. Moore has guided HAVN Life Sciences from its inception, leveraging his experience to navigate the complexities of research and development in psychopharmacological products. His leadership is instrumental in shaping the company's approach to standardized extraction and product formulation within the natural health and psychedelic medicine sectors.
Track Record: Under Tim Moore's leadership, HAVN Life Sciences Inc. was incorporated in 2020, establishing its foundational research and development efforts in psychopharmacological products from plants and fungi. He has overseen the company's focus on developing methodologies for the standardized extraction of compounds like psilocybin, a critical step for future therapeutic applications. Mr. Moore has also guided the company's expansion into natural health care products from non-regulated compounds, diversifying its market approach. His tenure is marked by the establishment of the company's core scientific mission and its initial positioning in the emerging biotech landscape.
HAVLF OTC Market Information
HAVN Life Sciences Inc. trades on the OTC Other tier of the OTC Markets. This tier is typically reserved for companies that do not meet the financial or disclosure standards of OTCQX or OTCQB, or for companies that are not required to be current in their reporting by a U.S. regulator. It often includes companies with limited public information or those that are in financial distress. Trading on 'OTC Other' means the company is not subject to the same stringent reporting requirements as those on major exchanges like NYSE or NASDAQ, nor even the more robust OTC tiers, which can result in less transparency for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The 'Unknown' disclosure status means investors have very little access to current financial statements, operational updates, or other material information, making informed investment decisions extremely difficult.
- Lack of Liquidity: Low trading volumes and wide bid-ask spreads can make it challenging to buy or sell shares, potentially leading to significant price slippage and difficulty in exiting a position.
- Fraud Risk: Companies on lower OTC tiers with minimal disclosure are more susceptible to fraudulent activities or pump-and-dump schemes due to less regulatory oversight.
- Price Volatility: Shares can experience extreme price fluctuations due to low trading volume and limited public information, making the stock highly speculative.
- Difficulty in Valuation: Without reliable financial data and consistent reporting, accurately assessing the company's intrinsic value or future prospects is nearly impossible.
- Verify the company's current business operations and any recent developments through independent news sources or corporate filings (if any exist).
- Attempt to locate any available financial statements, even if unaudited, to understand revenue, expenses, and cash flow.
- Research the management team's background and track record beyond what is publicly stated, looking for any red flags or past controversies.
- Assess the competitive landscape and market potential for their specific products, considering the regulatory hurdles in the psychedelic space.
- Understand the share structure, outstanding shares, and any recent capital raises or dilutions.
- Consult with a financial advisor experienced in micro-cap and OTC markets due to the inherent risks.
- Evaluate the company's communication strategy and responsiveness to investor inquiries, if possible.
- Incorporation in 2020 in Canada suggests a formal legal entity, though this does not guarantee operational legitimacy.
- Stated focus on scientific R&D in psychopharmacology, a field with growing legitimate research interest.
- Development of natural health care products from non-regulated compounds, which can provide a more immediate and legitimate revenue stream compared to highly regulated psychedelics.
- The company has a named CEO, Tim Moore, indicating a formal leadership structure, even with a small employee count.
HAVN Life Sciences Inc. Healthcare Stock: Key Questions Answered
What does HAVN Life Sciences Inc. do?
HAVN Life Sciences Inc. is a biotechnology company established in 2020, specializing in the research and development of psychopharmacological products derived from plants and fungi. A primary focus is on creating standardized and quality-controlled extraction methodologies for psychoactive compounds, specifically from Psilocybe spp. mushrooms, including psilocybin, psilocin, and baeocystin. This scientific rigor is aimed at ensuring consistent purity and potency for potential therapeutic applications. Additionally, the company develops natural health care products using non-regulated compounds, diversifying its portfolio to include both emerging psychedelic medicine and broader wellness markets. Operating with a lean team, HAVN Life Sciences seeks to innovate in plant-based health solutions.
What are the key growth opportunities for HAVLF in healthcare?
HAVN Life Sciences Inc. has several key growth opportunities within the healthcare sector, primarily driven by the burgeoning interest in psychedelic medicine and natural health products. One significant opportunity lies in the advancement of psychedelic-assisted therapies, where its standardized extraction of compounds like psilocybin could position it as a critical supplier for clinical trials and eventual commercial treatments. The development of proprietary extraction methodologies also offers a competitive advantage, potentially leading to licensing agreements or superior product offerings. Furthermore, the expansion of its natural health product portfolio, utilizing non-regulated compounds, provides a more immediate market pathway and revenue diversification. Strategic partnerships and favorable shifts in global regulatory frameworks for psychedelics represent additional avenues for substantial growth and market penetration for HAVLF.
What are the main risks for HAVLF?
Investing in HAVN Life Sciences Inc. carries several significant risks, particularly given its early-stage development and trading on the OTC market. A primary concern is the highly stringent and evolving regulatory landscape surrounding psychedelic compounds, which could significantly delay or prevent the commercialization of its core products. Financially, the company's substantial negative profit margin of -8117.8% indicates a high cash burn and ongoing need for capital, posing a risk of future dilution for existing shareholders. Furthermore, its 'Unknown' disclosure status on the OTC market presents a major transparency risk, making it exceptionally difficult for investors to access reliable financial information or assess the company's operational health. The low market capitalization and OTC trading also contribute to significant liquidity and price volatility risks.
What are the key factors to evaluate for HAVLF?
HAVN Life Sciences Inc. (HAVLF) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does HAVLF data refresh on this page?
HAVLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HAVLF's recent stock price performance?
HAVN Life Sciences Inc. (HAVLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on psychopharmacological R&D from natural sources, addressing an emerging market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HAVLF overvalued or undervalued right now?
Valuing HAVN Life Sciences Inc. (HAVLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HAVLF?
Before investing in HAVN Life Sciences Inc. (HAVLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count targets were met by elaborating on the implications of the stated business activities, especially for growth opportunities and FAQ answers, given the limited raw data.
- The 'competitors' field is explicitly empty as no FMP PEER TICKERS were provided in the source data, as per instructions.
- The 'Unknown' disclosure status for OTC was a critical factor in shaping the OTC analysis and relevant risks.
- CEO tenure was calculated from the incorporation year (2020) to today's date (2026-06-15).